Global News Roundup: Q1-Q3 2021
We are pleased to launch the first edition of our quarterly Windrose Consulting Group: Global News Roundup for Q1-Q3 2021.
In this edition, our contributing editors, Amy Morgan and Kate Hogan look at many key changes in the Global Life Sciences industry, such as: the Canadian Government introducing several drug pricing reforms to reduce cost of patented drugs; the newly formed German Government set to reduce costs to the health system; Japan introducing cost-effectiveness into its health technology assessment (HTA) to limit rising healthcare expenditure and more.
Amy Morgan, Head of International Markets, Windrose Consulting Group (Contributing Editor)
Kate Hogan, Senior Consultant, Windrose Consulting Group (Contributing Editor)
Strategic guidance for Life Sciences.
Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their products—so they can meet today’s most critical healthcare needs.
We work across a broad range of products and disease areas with services that include product commercialization, pricing and market access and value communication.
We’re committed to helping companies succeed in bringing innovations to market that enhance people’s lives.
Windrose is a global organisation and have three offices, in Philadelphia (US), London (UK) and Lucerne (Switzerland).